[go: up one dir, main page]

CA2374117A1 - Formulations comprenant des agents regulateurs des lipides - Google Patents

Formulations comprenant des agents regulateurs des lipides Download PDF

Info

Publication number
CA2374117A1
CA2374117A1 CA002374117A CA2374117A CA2374117A1 CA 2374117 A1 CA2374117 A1 CA 2374117A1 CA 002374117 A CA002374117 A CA 002374117A CA 2374117 A CA2374117 A CA 2374117A CA 2374117 A1 CA2374117 A1 CA 2374117A1
Authority
CA
Canada
Prior art keywords
composition
lipid
excipient
fenofibrate
regulating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002374117A
Other languages
English (en)
Inventor
Devalina Law
Steven L. Krill
Eric A. Schmitt
James J. Fort
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2374117A1 publication Critical patent/CA2374117A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une formulation solide faite d'un mélange d'agent régulateur des lipides et d'un excipient, en l'occurrence un mélange eutectique.
CA002374117A 1999-05-28 2000-05-23 Formulations comprenant des agents regulateurs des lipides Abandoned CA2374117A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32318399A 1999-05-28 1999-05-28
US09/323,183 1999-05-28
PCT/US2000/014109 WO2000072829A1 (fr) 1999-05-28 2000-05-23 Formulations comprenant des agents regulateurs des lipides

Publications (1)

Publication Number Publication Date
CA2374117A1 true CA2374117A1 (fr) 2000-12-07

Family

ID=23258077

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002374117A Abandoned CA2374117A1 (fr) 1999-05-28 2000-05-23 Formulations comprenant des agents regulateurs des lipides

Country Status (5)

Country Link
EP (1) EP1183017A1 (fr)
JP (1) JP2003500439A (fr)
CA (1) CA2374117A1 (fr)
MX (1) MXPA01012225A (fr)
WO (1) WO2000072829A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
MEP27808A (en) 2001-01-26 2010-10-10 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
CA2504878A1 (fr) 2002-11-06 2004-05-27 Schering Corporation Inhibiteurs d'absorption du cholesterol pour le traitement de la demyelination
WO2004081002A1 (fr) 2003-03-07 2004-09-23 Schering Corporation Composes d'azetidinone substitues, leurs formulations et utilisations en vue du traitement de l'hypercholesterolemie
WO2004081003A1 (fr) 2003-03-07 2004-09-23 Schering Corporation Composes d'azetidinone substitues, leurs formulations et leur utilisation pour traiter l'hypercholesterolemie
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA06013252A (es) * 2004-05-14 2007-02-28 Emisphere Tech Inc Compuestos y composiciones para suministrar agentes activos.
GB2441499B (en) * 2006-09-08 2011-09-14 Jasin El Sammadoni Slimming Spray
DK2200588T3 (da) 2007-09-25 2019-07-01 Solubest Ltd Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
JP5437232B2 (ja) 2008-03-11 2014-03-12 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2157201C3 (de) * 1970-11-13 1974-12-12 Boehringer Mannheim Gmbh, 6800 Mannheim Verbesserte feste orale Applikationsform von Raubasin
IT1180507B (it) * 1984-06-29 1987-09-23 Roberto Valducci Procedimento per la preparazione di etofibrato o sostanze di pari o simili caratteristiche, in microgunuli-ritardo e prodotto ottenuto con tale procedimento
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
CA2124821C (fr) * 1991-12-18 2003-10-07 Isaac Ghebre-Sellassie Dispersions pharmaceutiques solides ameliorees

Also Published As

Publication number Publication date
EP1183017A1 (fr) 2002-03-06
JP2003500439A (ja) 2003-01-07
MXPA01012225A (es) 2002-08-12
WO2000072829A1 (fr) 2000-12-07

Similar Documents

Publication Publication Date Title
US6465011B2 (en) Formulations comprising lipid-regulating agents
US6372251B2 (en) Formulations comprising lipid-regulating agents
US4404183A (en) Sustained release pharmaceutical composition of solid medical material
EP0142561B1 (fr) Preparation a base de nifedipine a action prolongee
US6368622B2 (en) Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
EP1140036A2 (fr) Formulations comprenant des liporegulateurs
US6383517B1 (en) Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
EP1162954A1 (fr) Preparations contenant des agents regulateurs de lipides
CA2374117A1 (fr) Formulations comprenant des agents regulateurs des lipides
KR20100038188A (ko) 수분산성 건성 약학적 조성물의 신규 제조 방법 및 그에 의해 수득한 약학적 조성물
US6838091B2 (en) Formulations comprising lipid-regulating agents
MX2007012124A (es) Formulaciones mejoradas de fenofibrato.
JPH0157090B2 (fr)
US6814977B1 (en) Formulations comprising lipid-regulating agents
US8062664B2 (en) Process for preparing formulations of lipid-regulating drugs
JP2004536826A (ja) プラバスタチンを含む安定な薬剤組成物
US20020040046A1 (en) Novel formulations comprising lipid-regulating agents
US7014864B1 (en) Formulations comprising lipid-regulating agents
CA2531097C (fr) Procede de preparation de produits formules de medicaments de regulation du metabolisme lipidique
US20060177512A1 (en) Process for preparing formulations of lipid-regulating drugs

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead